Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Standard Biotools (LAB) Acquisitions (2020 - 2024)

Standard Biotools (LAB) has disclosed Acquisitions for 3 consecutive years, with -$278.6 million as the latest value for Q4 2024.

  • On a quarterly basis, Acquisitions changed N/A to -$278.6 million in Q4 2024 year-over-year; TTM through Dec 2024 was $1.4 million, a N/A change, with the full-year FY2024 number at $1.4 million, changed N/A from a year prior.
  • Acquisitions was -$278.6 million for Q4 2024 at Standard Biotools, down from $280.0 million in the prior quarter.
  • In the past five years, Acquisitions ranged from a high of $280.0 million in Q1 2024 to a low of -$278.6 million in Q4 2024.